The IL-24 gene protects human umbilical vein endothelial cells against H2O2-induced injury and may be useful as a treatment for cardiovascular disease

Wang,Zhaoxia; Wang,Yang; Chen,Yunfei; Lv,Jiyuan

doi:10.3892/ijmm.2016.2466

The IL-24 gene protects human umbilical vein endothelial cells against H2O2-induced injury and may be useful as a treatment for cardiovascular disease

Authors:
- Zhaoxia Wang
- Yang Wang
- Yunfei Chen
- Jiyuan Lv
View Affiliations

Affiliations: The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R. China, Bank of China Shanxi Branch, Taiyuan, Shanxi, P.R. China
Published online on: January 25, 2016 https://doi.org/10.3892/ijmm.2016.2466
Pages: 581-592
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the protective effects of interleukin-24 (IL-24) on hydrogen peroxide (H2O2)-induced vascular endothelial injury and to examine the association between IL-24 and cardiovascular disease. Human umbilical vein endothelial cells (HUVECs) were exposed to increasing concentrations of H2O2 in the presence or absence of IL-24, which was introduced via Lipofectamine® 2000-mediated transfection. The successful uptake of the IL-24 plasmid was confirmed by RT-PCR at 24 h post-transfection. The effects of H2O2 and IL-24 on the proliferation and migration of the HUVECs was determined using cell migration assays. Cell viability was determined using a Cell Counting Kit-8 (CCK-8). Apoptosis and the measurement of the intracellular reactive oxygen species (ROS) levels were determined by flow cytometry, and the levels of caspase-3, which is associated with apoptosis, were determined by western blot analysis. Real‑time PCR and western blot analysis were also used to measure the levels of multiple cardiovascular disease‑associated factors. In vivo experiments were also performed using a rat model of hypertension which was constructed by angiotensin II infusion using an osmotic pump. The mRNA and protein levels of IL-24 were measured in both the control and hypertensive rats; the effects of treatment with enalapril and nifedipine on the IL-24 levels were also examined. Our results revealed that IL-24 protected against the H2O2-mediated abnormal increase in HUVEC proliferation. IL-24 also antagonized H2O2 by reducing the content of ROS in the cells, thus decreasing cellular oxidative damage, improving the cellular survival rate, reducing apoptosis and decreasing the expression of cardiovascular disease-related factors. The results from our in vivo animal experiments revealed that IL-24 expression was lower in the hypertensive rats compared to the healthy controls. Additionally, the IL-24 levels increased following anti-hypertensive therapy. The findings of our study indicate that IL-24 protects against H2O2-mediated endothelial cell damage and may thus provide a novel therapeutic strategy for treatment of cardiovascular disease.

View Figures

View References

1	Cohuet G and Struijker-Boudier H: Mechanisms of target organ damage caused by hypertension: Therapeutic potential. Pharmacol Ther. 111:81–98. 2006. View Article : Google Scholar
2	Lugo-Baruqui A, Munoz-Valle JF, Arevalo-Gallegos S and Armendariz-Borunda J: Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. Hepatol Res. 40:95–104. 2010. View Article : Google Scholar
3	Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al: European Society of Cardiology: 2007 ESH-ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 16:135–232. 2007. View Article : Google Scholar
4	Okuda T, Sumiya T, Mizutani K, Tago N, Miyata T, Tanabe T, Kato H, Katsuya T, Higaki J, Ogihara T, et al: Analyses of differential gene expression in genetic hypertensive rats by microarray. Hypertens Res. 25:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
5	Yono M, Yoshida M, Yamamoto Y, Imanishi A, Fukagawa A, Latifpour J and Eto M: Identification of potential therapeutic targets in hypertension-associated bladder dysfunction. BJU Int. 105:877–883. 2010. View Article : Google Scholar
6	Lee KM, Kang HA, Ko CB, Oh EH, Park M, Lee HY, Choi HR, Yun CH, Jung WW, Oh JW and Kang HS: Differential gene expression profiles in spontaneously hypertensive rats induced by administration of enalapril and nifedipine. Int J Mol Med. 31:179–187. 2013.
7	Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS and Fisher PB: The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA. 93:9160–9165. 1996. View Article : Google Scholar : PubMed/NCBI
8	Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S and Grimm EA: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 168:6041–6046. 2002. View Article : Google Scholar : PubMed/NCBI
9	Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, Kawabe S, Branch CD, Zumstein L, Meyn RE, Roth JA, et al: Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 21:4558–4566. 2002. View Article : Google Scholar : PubMed/NCBI
10	Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S and Grimm EA: Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 20:1069–1074. 2002. View Article : Google Scholar : PubMed/NCBI
11	Ross JS, Stagliano NE, Donovan MJ, Breitbart RE and Ginsburg GS: Atherosclerosis: A cancer of the blood vessels? Am J Clin Pathol. 116(Suppl): S97–S107. 2001.
12	Menezes ME, Shen XN, Das SK, Emdad L, Guo C, Yuan F, Li YJ, Archer MC, Zacksenhaus E, Windle JJ, et al: MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer. Oncotarget. 6:36928–36942. 2015.PubMed/NCBI
13	Lin C, Liu H, Li L, Zhu Q, Liu H, Ji Z, Liao J, Lang J, Wu J and Fan J: MDA-7/IL-24 inhibits cell survival by inducing apoptosis in nasopharyngeal carcinoma. Int J Clin Exp Med. 7:4082–4090. 2014.
14	Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S, Dent P, Wang XY, Sarkar D and Fisher PB: MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol. 818:127–153. 2014. View Article : Google Scholar : PubMed/NCBI
15	Fliss H and Gattinger D: Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 79:949–956. 1996. View Article : Google Scholar : PubMed/NCBI
16	Hampton MB and Orrenius S: Redox regulation of apoptotic cell death. Biofactors. 8:1–5. 1998. View Article : Google Scholar : PubMed/NCBI
17	Ying W: Deleterious network hypothesis of apoptosis. Med Hypotheses. 50:393–398. 1998. View Article : Google Scholar : PubMed/NCBI
18	Puddu P, Puddu GM, Zaca F and Muscari A: Endothelial dysfunction in hypertension. Acta Cardiol. 55:221–232. 2000. View Article : Google Scholar : PubMed/NCBI
19	Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS and Leiden JM: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:518–522. 1995. View Article : Google Scholar : PubMed/NCBI
20	Ascher E, Scheinman M, Hingorani A, Seth P, Marella VK and Jacob T: Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann Vasc Surg. 14:385–392. 2000. View Article : Google Scholar : PubMed/NCBI
21	Chang MW, Barr E, Lu MM, Barton K and Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 96:2260–2268. 1995. View Article : Google Scholar : PubMed/NCBI
22	Huang J and Kontos CD: Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol. 22:745–751. 2002. View Article : Google Scholar : PubMed/NCBI
23	Xue B, Pamidimukkala J and Hay M: Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol. 288:H2177–H2184. 2005. View Article : Google Scholar : PubMed/NCBI
24	Rugale C, Delbosc S, Cristol JP, Mimran A and Jover B: Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol. 284:H1744–H1750. 2003. View Article : Google Scholar : PubMed/NCBI
25	Burdon RH and Gill V: Cellularly generated active oxygen species and HeLa cell proliferation. Free Radic Res Commun. 19:203–213. 1993. View Article : Google Scholar : PubMed/NCBI
26	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
27	Rao GN and Berk BC: Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 70:593–599. 1992. View Article : Google Scholar : PubMed/NCBI
28	Touyz RM and Schiffrin EL: Reactive oxygen species in vascular biology: Implications in hypertension. Histochem Cell Biol. 122:339–352. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ruef J, Hu ZY, Yin LY, Wu Y, Hanson SR, Kelly AB, Harker LA, Rao GN, Runge MS and Patterson C: Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ Res. 81:24–33. 1997. View Article : Google Scholar : PubMed/NCBI
30	Chua CC, Hamdy RC and Chua BH: Upregulation of vascular endothelial growth factor by H₂O₂ in rat heart endothelial cells. Free Radic Biol Med. 25:891–897. 1998. View Article : Google Scholar : PubMed/NCBI
31	Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, Friesema EC, Russcher H, van den Meiracker AH, Visser W and Danser AH: Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 65:1316–1323. 2015. View Article : Google Scholar : PubMed/NCBI
32	Puddu P, Puddu GM, Cravero E, Ferrari E and Muscari A: The genetic basis of essential hypertension. Acta Cardiol. 62:281–293. 2007. View Article : Google Scholar : PubMed/NCBI
33	Hollenberg NK: Genes, hypertension, and intermediate phenotypes. Curr Opin Cardiol. 11:457–463. 1996. View Article : Google Scholar : PubMed/NCBI
34	Zou Y, Hu Y, Metzler B and Xu Q: Signal transduction in arterio-sclerosis: mechanical stress-activated MAP kinases in vascular smooth muscle cells (review). Int J Mol Med. 1:827–834. 1998.PubMed/NCBI
35	von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP and Dzau VJ: Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1137–1141. 1995. View Article : Google Scholar : PubMed/NCBI
36	Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y, Komori K, Sugimachi K and Sueishi K: Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 82:147–156. 1998. View Article : Google Scholar : PubMed/NCBI
37	Markowitz SD: Atherosclerosis, just another cancer? J Clin Invest. 100:2143–2145. 1997. View Article : Google Scholar : PubMed/NCBI
38	Ross JS, Stagliano NE, Donovan MJ, Breitbart RE and Ginsburg GS: Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 947:271–292; discussion 292–273. 2001. View Article : Google Scholar
39	Schwartz SM, deBlois D and O'Brien ER: The intima. Soil for atherosclerosis and restenosis. Circ Res. 77:445–465. 1995. View Article : Google Scholar : PubMed/NCBI
40	Davies MG and Hagen PO: Pathobiology of intimal hyperplasia. Br J Surg. 81:1254–1269. 1994. View Article : Google Scholar : PubMed/NCBI
41	Chen J, Chada S, Mhashilkar A and Miano JM: Tumor suppressor MDA-7/IL-24 selectively inhibits vascular smooth muscle cell growth and migration. Mol Ther. 8:220–229. 2003. View Article : Google Scholar : PubMed/NCBI
42	Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, et al: Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 63:5105–5113. 2003.PubMed/NCBI
43	Lee KM, Kang HA, Park M, Lee HY, Choi HR, Yun CH, Oh JW and Kang HS: Interleukin-24 attenuates β-glycerophosphate-induced calcification of vascular smooth muscle cells by inhibiting apoptosis, the expression of calcification and osteoblastic markers, and the Wnt/β-catenin pathway. Biochem Biophys Res Commun. 428:50–55. 2012. View Article : Google Scholar : PubMed/NCBI
44	Lee KM, Kang HA, Park M, Lee HY, Song MJ, Ko K, Oh JW and Kang HS: Interleukin-24 suppresses the growth of vascular smooth muscle cells by inhibiting H(2)O(2)-induced reactive oxygen species production. Pharmacology. 90:332–341. 2012. View Article : Google Scholar : PubMed/NCBI
45	Vargas-Alarcon G, Posadas-Romero C, Villarreal-Molina T, Alvarez-León E, Angeles-Martinez J, Posadas-Sanchez R, Monroy-Muñoz I, Luna-Fuentes S, González-Salazar C, Ramirez-Bello J, et al: IL-24 gene polymorphisms are associated with cardiometabolic parameters and cardiovascular risk factors but not with premature coronary artery disease: the genetics of atherosclerotic disease Mexican study. J Interferon Cytokine Res. 34:659–666. 2014. View Article : Google Scholar : PubMed/NCBI
46	Yacoub A, Mitchell C, Lister A, Lebedeva IV, Sarkar D, Su ZZ, Sigmon C, McKinstry R, Ramakrishnan V, Qiao L, et al: Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 9:3272–3281. 2003.PubMed/NCBI
47	Shimokawa H: Endothelial dysfunction in hypertension. J Atheroscler Thromb. 4:118–127. 1998. View Article : Google Scholar : PubMed/NCBI
48	McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM and McCance DR: Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond). 97:141–147. 1999. View Article : Google Scholar
49	Panneerselvam J, Jin J, Shanker M, Lauderdale J, Bates J, Wang Q, Zhao YD, Archibald SJ, Hubin TJ and Ramesh R: IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 10:e01224392015. View Article : Google Scholar : PubMed/NCBI
50	Ma Q, Deng X, Jin B, Zhang Y, Luo D, Song H, Wang P, Zhang C, Li X, Shi Y, et al: A novel human interleukin-24 peptide created by computer-guided design contributes to suppression of proliferation in esophageal squamous cell carcinoma Eca-109 cells. Oncol Rep. 33:193–200. 2015.
51	Jiang G, Yang CS, Xu D, Sun C, Zheng JN, Lei TC and Liu YQ: Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion. Br J Cancer. 110:2496–2505. 2014. View Article : Google Scholar : PubMed/NCBI
52	Yang R, Hai C, Li R and Wu D: Dose-response relationship between cell proliferation and hydrogen peroxide. Carcinog Teratog Mutagen. 9:92–98. 1997.
53	Li L, Wei Y, Cai J, et al: Hydrogen peroxide induced apoptosis in humanvascular endothelial cells in vitro and expression of Caspase-3. Shaanxi Medical Journal. 37:960–961. 2008.
54	Chen QM, Tu VC, Wu Y and Bahl JJ: Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardio-myocytes. Arch Biochem Biophys. 373:242–248. 2000. View Article : Google Scholar : PubMed/NCBI